Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis

Kathryn M. Ryder, S. Bobo Tanner, Laura Carbone, John E. Williams, Henry M. Taylor, Andrew Bush, Victorina Pintea, Mitchell A. Watsky

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Institutionalized adults with severe developmental disabilities have a high rate of minimal trauma and appendicular fracture. There is little information about osteoporosis treatment in this population. In this efficacy and safety study, men and women with severe developmental disabilities and osteoporosis received 20 mcg teriparatide subcutaneously daily for 18-24 months. Markers of bone formation [procollagen type 1 intact N-terminal propeptide (P1NP)] and resorption [C-telopeptide (CTx)] were measured at three-month intervals. Serum calcium was measured at two-week intervals for 12 weeks and thereafter at three-month intervals. Twenty-seven individuals received at least one injection. The incidence of hypercalcemia was 11.1% but was persistent and led to medication discontinuation in only one participant. Biomarkers of bone formation increased rapidly, doubling by three months. At 12 months, P1NP and CTx remained elevated from baseline; P1NP had risen from 66.95 ± 83.71 μg/l (mean ± SD) to 142.42 ± 113.85 μg/l (P = 0.05), and CTx had increased from 0.377 ± 0.253 to 1.016 ± 1.048 ng/ml (P = 0.01). The majority of participants had an increase in P1NP of over 10 μg/l. In conclusion, teriparatide is safe and effective in developmentally disabled institutionalized adults. Serial calcium measurements are warranted, particularly during the first three months of therapy.

Original languageEnglish (US)
Pages (from-to)233-239
Number of pages7
JournalJournal of Bone and Mineral Metabolism
Volume28
Issue number2
DOIs
StatePublished - Mar 1 2010
Externally publishedYes

Fingerprint

Teriparatide
Collagen Type I
Osteoporosis
Biomarkers
Bone and Bones
Developmental Disabilities
Osteogenesis
Calcium
Hypercalcemia
Safety
Injections
Incidence
Wounds and Injuries
Therapeutics
Serum
Population

Keywords

  • Biomarkers
  • Developmental disabilities
  • Disuse osteoporosis
  • Institutionalized
  • Teriparatide

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine
  • Endocrinology

Cite this

Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis. / Ryder, Kathryn M.; Bobo Tanner, S.; Carbone, Laura; Williams, John E.; Taylor, Henry M.; Bush, Andrew; Pintea, Victorina; Watsky, Mitchell A.

In: Journal of Bone and Mineral Metabolism, Vol. 28, No. 2, 01.03.2010, p. 233-239.

Research output: Contribution to journalArticle

Ryder, Kathryn M. ; Bobo Tanner, S. ; Carbone, Laura ; Williams, John E. ; Taylor, Henry M. ; Bush, Andrew ; Pintea, Victorina ; Watsky, Mitchell A. / Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis. In: Journal of Bone and Mineral Metabolism. 2010 ; Vol. 28, No. 2. pp. 233-239.
@article{5107b0cfbf82436998fec43144b0ab7a,
title = "Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis",
abstract = "Institutionalized adults with severe developmental disabilities have a high rate of minimal trauma and appendicular fracture. There is little information about osteoporosis treatment in this population. In this efficacy and safety study, men and women with severe developmental disabilities and osteoporosis received 20 mcg teriparatide subcutaneously daily for 18-24 months. Markers of bone formation [procollagen type 1 intact N-terminal propeptide (P1NP)] and resorption [C-telopeptide (CTx)] were measured at three-month intervals. Serum calcium was measured at two-week intervals for 12 weeks and thereafter at three-month intervals. Twenty-seven individuals received at least one injection. The incidence of hypercalcemia was 11.1{\%} but was persistent and led to medication discontinuation in only one participant. Biomarkers of bone formation increased rapidly, doubling by three months. At 12 months, P1NP and CTx remained elevated from baseline; P1NP had risen from 66.95 ± 83.71 μg/l (mean ± SD) to 142.42 ± 113.85 μg/l (P = 0.05), and CTx had increased from 0.377 ± 0.253 to 1.016 ± 1.048 ng/ml (P = 0.01). The majority of participants had an increase in P1NP of over 10 μg/l. In conclusion, teriparatide is safe and effective in developmentally disabled institutionalized adults. Serial calcium measurements are warranted, particularly during the first three months of therapy.",
keywords = "Biomarkers, Developmental disabilities, Disuse osteoporosis, Institutionalized, Teriparatide",
author = "Ryder, {Kathryn M.} and {Bobo Tanner}, S. and Laura Carbone and Williams, {John E.} and Taylor, {Henry M.} and Andrew Bush and Victorina Pintea and Watsky, {Mitchell A.}",
year = "2010",
month = "3",
day = "1",
doi = "10.1007/s00774-009-0123-1",
language = "English (US)",
volume = "28",
pages = "233--239",
journal = "Journal of Bone and Mineral Metabolism",
issn = "0914-8779",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis

AU - Ryder, Kathryn M.

AU - Bobo Tanner, S.

AU - Carbone, Laura

AU - Williams, John E.

AU - Taylor, Henry M.

AU - Bush, Andrew

AU - Pintea, Victorina

AU - Watsky, Mitchell A.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Institutionalized adults with severe developmental disabilities have a high rate of minimal trauma and appendicular fracture. There is little information about osteoporosis treatment in this population. In this efficacy and safety study, men and women with severe developmental disabilities and osteoporosis received 20 mcg teriparatide subcutaneously daily for 18-24 months. Markers of bone formation [procollagen type 1 intact N-terminal propeptide (P1NP)] and resorption [C-telopeptide (CTx)] were measured at three-month intervals. Serum calcium was measured at two-week intervals for 12 weeks and thereafter at three-month intervals. Twenty-seven individuals received at least one injection. The incidence of hypercalcemia was 11.1% but was persistent and led to medication discontinuation in only one participant. Biomarkers of bone formation increased rapidly, doubling by three months. At 12 months, P1NP and CTx remained elevated from baseline; P1NP had risen from 66.95 ± 83.71 μg/l (mean ± SD) to 142.42 ± 113.85 μg/l (P = 0.05), and CTx had increased from 0.377 ± 0.253 to 1.016 ± 1.048 ng/ml (P = 0.01). The majority of participants had an increase in P1NP of over 10 μg/l. In conclusion, teriparatide is safe and effective in developmentally disabled institutionalized adults. Serial calcium measurements are warranted, particularly during the first three months of therapy.

AB - Institutionalized adults with severe developmental disabilities have a high rate of minimal trauma and appendicular fracture. There is little information about osteoporosis treatment in this population. In this efficacy and safety study, men and women with severe developmental disabilities and osteoporosis received 20 mcg teriparatide subcutaneously daily for 18-24 months. Markers of bone formation [procollagen type 1 intact N-terminal propeptide (P1NP)] and resorption [C-telopeptide (CTx)] were measured at three-month intervals. Serum calcium was measured at two-week intervals for 12 weeks and thereafter at three-month intervals. Twenty-seven individuals received at least one injection. The incidence of hypercalcemia was 11.1% but was persistent and led to medication discontinuation in only one participant. Biomarkers of bone formation increased rapidly, doubling by three months. At 12 months, P1NP and CTx remained elevated from baseline; P1NP had risen from 66.95 ± 83.71 μg/l (mean ± SD) to 142.42 ± 113.85 μg/l (P = 0.05), and CTx had increased from 0.377 ± 0.253 to 1.016 ± 1.048 ng/ml (P = 0.01). The majority of participants had an increase in P1NP of over 10 μg/l. In conclusion, teriparatide is safe and effective in developmentally disabled institutionalized adults. Serial calcium measurements are warranted, particularly during the first three months of therapy.

KW - Biomarkers

KW - Developmental disabilities

KW - Disuse osteoporosis

KW - Institutionalized

KW - Teriparatide

UR - http://www.scopus.com/inward/record.url?scp=77952479638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952479638&partnerID=8YFLogxK

U2 - 10.1007/s00774-009-0123-1

DO - 10.1007/s00774-009-0123-1

M3 - Article

VL - 28

SP - 233

EP - 239

JO - Journal of Bone and Mineral Metabolism

JF - Journal of Bone and Mineral Metabolism

SN - 0914-8779

IS - 2

ER -